Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Renoprotection Provided by Additional Diuretic Treatment in Partially Nephrectomized Ren-2 Transgenic Rats Subjected to the Combined RAS and ETA Blockade

I. Vaněčková, S. Hojná, Z. Vernerová, M. Kadlecová, H. Rauchová, E. Kompanowska-Jezierska, Z. Vaňourková, L. Červenka, J. Zicha,

. 2019 ; 10 (-) : 1145. [pub] 20190918

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19044200

Grant support
NV15-25396A MZ0 CEP Register

Objective: Our previous study in heterozygous Ren-2 transgenic rats (TGR) demonstrated that long-term treatment with endothelin receptor A (ETA) blocker atrasentan added to the renin-angiotensin system (RAS) blockade had renoprotective effects in a model of chronic kidney disease (CKD) induced by partial nephrectomy. Since ETA blockade is known to cause edema, we were interested whether diuretic treatment added to this therapy would be beneficial. Design and Methods: Partial nephrectomy (NX) was performed at the age of 3 months in TGR rats which were subjected to: (i) RAS blockade alone (angiotensin receptor blocker losartan and angiotensin converting enzyme inhibitor trandolapril), (ii) combined RAS (losartan and trandolapril) and ETA receptor blockade (atrasentan), or (iii) diuretic (hydrochlorothiazide) added to the combined RAS + ETA blockade for 50 weeks following NX. Results: At the end of the study systolic blood pressure and cardiac hypertrophy were similarly decreased in all treated groups. Survival was significantly improved by ETA receptor blockade added to RAS blockade with no further effects of diuretic treatment. However, additional diuretic treatment combined with RAS + ETA blockade decreased body weight and had beneficial renoprotective effects - reductions of both kidney weight and kidney damage markers. Proteinuria gradually increased in rats treated with RAS blockade alone, while it was substantially lowered by additional ETA blockade. In rats treated with additional diuretic, proteinuria was progressively reduced throughout the experiment. Conclusion: A diuretic added to the combined RAS and ETA blockade has late renoprotective effects in CKD induced by partial nephrectomy in Ren-2 transgenic rats. The diuretic improved: renal function (evaluated as proteinuria and creatinine clearance), renal morphology (kidney mass, glomerular volume), and histological markers of kidney damage (glomerulosclerosis index, tubulointerstitial injury).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044200
003      
CZ-PrNML
005      
20200109095602.0
007      
ta
008      
200107s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphys.2019.01145 $2 doi
035    __
$a (PubMed)31620007
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vaněčková, Ivana $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
245    10
$a Renoprotection Provided by Additional Diuretic Treatment in Partially Nephrectomized Ren-2 Transgenic Rats Subjected to the Combined RAS and ETA Blockade / $c I. Vaněčková, S. Hojná, Z. Vernerová, M. Kadlecová, H. Rauchová, E. Kompanowska-Jezierska, Z. Vaňourková, L. Červenka, J. Zicha,
520    9_
$a Objective: Our previous study in heterozygous Ren-2 transgenic rats (TGR) demonstrated that long-term treatment with endothelin receptor A (ETA) blocker atrasentan added to the renin-angiotensin system (RAS) blockade had renoprotective effects in a model of chronic kidney disease (CKD) induced by partial nephrectomy. Since ETA blockade is known to cause edema, we were interested whether diuretic treatment added to this therapy would be beneficial. Design and Methods: Partial nephrectomy (NX) was performed at the age of 3 months in TGR rats which were subjected to: (i) RAS blockade alone (angiotensin receptor blocker losartan and angiotensin converting enzyme inhibitor trandolapril), (ii) combined RAS (losartan and trandolapril) and ETA receptor blockade (atrasentan), or (iii) diuretic (hydrochlorothiazide) added to the combined RAS + ETA blockade for 50 weeks following NX. Results: At the end of the study systolic blood pressure and cardiac hypertrophy were similarly decreased in all treated groups. Survival was significantly improved by ETA receptor blockade added to RAS blockade with no further effects of diuretic treatment. However, additional diuretic treatment combined with RAS + ETA blockade decreased body weight and had beneficial renoprotective effects - reductions of both kidney weight and kidney damage markers. Proteinuria gradually increased in rats treated with RAS blockade alone, while it was substantially lowered by additional ETA blockade. In rats treated with additional diuretic, proteinuria was progressively reduced throughout the experiment. Conclusion: A diuretic added to the combined RAS and ETA blockade has late renoprotective effects in CKD induced by partial nephrectomy in Ren-2 transgenic rats. The diuretic improved: renal function (evaluated as proteinuria and creatinine clearance), renal morphology (kidney mass, glomerular volume), and histological markers of kidney damage (glomerulosclerosis index, tubulointerstitial injury).
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hojná, Silvie $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
700    1_
$a Vernerová, Zdenka $u Department of Pathology, Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Kadlecová, Michaela $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
700    1_
$a Rauchová, Hana $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
700    1_
$a Kompanowska-Jezierska, Elzbieta $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
700    1_
$a Vaňourková, Zdeňka $u Institute for Clinical and Experimental Medicine, Prague, Czechia.
700    1_
$a Červenka, Luděk $u Institute for Clinical and Experimental Medicine, Prague, Czechia.
700    1_
$a Zicha, Josef $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
773    0_
$w MED00174601 $t Frontiers in physiology $x 1664-042X $g Roč. 10, č. - (2019), s. 1145
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31620007 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200107 $b ABA008
991    __
$a 20200109095931 $b ABA008
999    __
$a ind $b bmc $g 1480789 $s 1082870
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 10 $c - $d 1145 $e 20190918 $i 1664-042X $m Frontiers in physiology $n Front. physiol. $x MED00174601
GRA    __
$a NV15-25396A $p MZ0
LZP    __
$a Pubmed-20200107

Find record

Citation metrics

Archiving options